Clinical Trial Update: Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing 18F-Florbetaben PET imaging in subjects with subjective cognitive decline has been withdrawn. The study will not proceed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subjective Cognitive Decline

Drugs mentioned

• 18F-Florbetaben

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Subjective Cognitive Decline | Phase 2 | Status: WITHDRAWN